Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $52.37 million. The enterprise value is $38.99 million.
Important Dates
The last earnings date was Wednesday, March 4, 2026, after market close.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 42.24 million shares outstanding. The number of shares has increased by 4.03% in one year.
| Current Share Class | 42.24M |
| Shares Outstanding | 42.24M |
| Shares Change (YoY) | +4.03% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 5.16% |
| Owned by Institutions (%) | 74.14% |
| Float | 37.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.58 |
| Forward PS | 0.57 |
| PB Ratio | 0.95 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.07, with a Debt / Equity ratio of 1.04.
| Current Ratio | 5.07 |
| Quick Ratio | 4.11 |
| Debt / Equity | 1.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.01 |
Financial Efficiency
Return on equity (ROE) is -77.19% and return on invested capital (ROIC) is -26.54%.
| Return on Equity (ROE) | -77.19% |
| Return on Assets (ROA) | -22.96% |
| Return on Invested Capital (ROIC) | -26.54% |
| Return on Capital Employed (ROCE) | -49.13% |
| Weighted Average Cost of Capital (WACC) | 4.64% |
| Revenue Per Employee | $305,733 |
| Profits Per Employee | -$182,443 |
| Employee Count | 296 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.43 |
Taxes
In the past 12 months, Pulmonx has paid $626,000 in taxes.
| Income Tax | 626,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.98% in the last 52 weeks. The beta is 0.11, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -81.98% |
| 50-Day Moving Average | 1.60 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 33.50 |
| Average Volume (20 Days) | 798,053 |
Short Selling Information
The latest short interest is 3.30 million, so 7.81% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short Previous Month | 3.32M |
| Short % of Shares Out | 7.81% |
| Short % of Float | 8.83% |
| Short Ratio (days to cover) | 4.64 |
Income Statement
In the last 12 months, Pulmonx had revenue of $90.50 million and -$54.00 million in losses. Loss per share was -$1.33.
| Revenue | 90.50M |
| Gross Profit | 67.14M |
| Operating Income | -53.66M |
| Pretax Income | -53.38M |
| Net Income | -54.00M |
| EBITDA | -52.61M |
| EBIT | -53.66M |
| Loss Per Share | -$1.33 |
Full Income StatementBalance Sheet
The company has $69.75 million in cash and $56.36 million in debt, with a net cash position of $13.39 million or $0.32 per share.
| Cash & Cash Equivalents | 69.75M |
| Total Debt | 56.36M |
| Net Cash | 13.39M |
| Net Cash Per Share | $0.32 |
| Equity (Book Value) | 54.12M |
| Book Value Per Share | 1.30 |
| Working Capital | 81.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.38 million and capital expenditures -$452,000, giving a free cash flow of -$32.83 million.
| Operating Cash Flow | -32.38M |
| Capital Expenditures | -452,000 |
| Depreciation & Amortization | 1.05M |
| Net Borrowing | -100,000 |
| Free Cash Flow | -32.83M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 74.19%, with operating and profit margins of -59.30% and -59.67%.
| Gross Margin | 74.19% |
| Operating Margin | -59.30% |
| Pretax Margin | -58.98% |
| Profit Margin | -59.67% |
| EBITDA Margin | -58.13% |
| EBIT Margin | -59.30% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.03% |
| Shareholder Yield | -4.03% |
| Earnings Yield | -103.11% |
| FCF Yield | -62.68% |
Analyst Forecast
The average price target for Pulmonx is $5.38, which is 333.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.38 |
| Price Target Difference | 333.87% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 32.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -4.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.38 |
| Piotroski F-Score | 3 |
